ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
1 story in the last 7 days
The latest protac news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks protac across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.

AI-designed drug rentosertib showed +98.4 mL lung capacity gain in a Phase IIa IPF trial, marking the first clean clinical proof for a machine-created medicine. The FDA approved vepdegestrant (Veppanu) on May 1, 2026, the first PROTAC degrader, for ESR1-mutated breast cancer.
Summaries by ByteBrief